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Abstract
Background: The treatment and control of schistosomiasis, an often neglected tropical disease that exacerbates poverty,
depends on a single drug, praziquantel. The large-scale use of praziquantel might select for drug-resistant parasites, hence
there is a need to develop new antischistosomal compounds. Here, we report that the antimalarial drug mefloquine
possesses promising antischistosomal properties in mice.
Methodology/Principal Findings: A single dose of mefloquine (200 or 400 mg/kg) administered orally to mice infected with
adult Schistosoma mansoni or adult S. japonicum resulted in high or complete total and female worm burden reductions
(72.3%–100%). Importantly, high worm burden reductions were also observed for young developing stages of S. mansoni
and S. japonicum harbored in the mouse. Both mefloquine erythro-enantiomers resulted in high and comparable total and
female worm burden reductions when given to mice with either a sub-patent or patent S. mansoni infection.
Conclusions/Significance: Our findings hold promise for the development of a novel antischistosomal drug based on an
aminoalcohol functionality. Further in vitro and in vivo studies have been launched to elucidate the possible mechanism of
action and to study the effect of mefloquine on S. haematobium and other trematodes. It will be interesting to investigate
whether mefloquine, which is widely and effectively used for the treatment of malaria, has an impact on schistosomiasis in
areas where both malaria and schistosomiasis co-exist.
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Introduction
Schistosomiasis is a chronic and debilitating disease that
exacerbates poverty [1,2]. Although close to 800 million
individuals are at risk of contracting the disease and over 200
million people are thought to be infected, schistosomiasis is often
neglected [3,4]. The causative agent is a digenetic trematode of the
genus Schistosoma. The three main species parasitizing humans are
S. haematobium, S. japonicum, and S. mansoni. Morbidity due to
schistosomiasis includes hepatic and intestinal fibrosis (S. mansoni
and S. japonicum), and ureteric and bladder fibrosis and calcification
of the genitourinary tract (S. haematobium) [5]. The global burden of
schistosomiasis has been estimated at 1.7 to 4.5 million disability-
adjusted life years (DALYs), but even the higher estimate might be
an underestimation of the true burden [2,6,7].
The treatment and control of schistosomiasis virtually relies on a
single drug, praziquantel. The pressing need to develop new
antischistosomal compounds has been emphasized [8–11], particu-
larly in view of blanket application of praziquantel within the frame
of ‘preventive chemotherapy’ [12], a strategy that might select for
drug-resistant parasites. Additionally, there is an important deficien-
cy in the therapeutic profile of praziquantel. The drug targets the
adult worm, but has only minor activity against the young
developing stages (i.e., schistosomula); hence, retreatment is
necessary to kill those parasites that have since matured. There is
no dedicated drug discovery and development program pursued for
schistosomiasis, either by the pharmaceutical industry or through
public-private partnerships. However, despite the paucity of a
concerted effort to develop novel antischistosomal drugs, a number
of compounds with promising antischistosomal properties have been
identified by academia, such as the synthetic trioxolanes [13], the
cysteine protease inhibitor K11777 [14], alkylaminoalkanethiosul-
furic acids [15], praziquantel analogs [16] and, most recently, the
oxadiazoles [10]. Nonetheless, to develop a new antischistosomal
drug from lead drug candidates will take at least another decade.
Underlying reasons are the scarce resources available for schistoso-
miasis and other neglected tropical diseases and the high failure rates
of compounds during preclinical and clinical testing [17].
Interestingly, the artemisinins (e.g., artemether and artesunate),
which are essential components of malaria treatment and control
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vivo studies revealed that schistosomula are particularly susceptible
to the artemisinins, whereas moderate worm burden reductions
are still apparent for adult worms [21]. A number of clinical trials
carried out in different African settings confirmed that both
artemether and artesunate have an effect against patent infections
with S. haematobium and S. mansoni [20,22]. Artemisinin-based
combination therapies (ACTs) have been adopted as first-line
drugs for uncomplicated Plasmodium falciparum malaria in most
malaria-endemic countries as a strategy to avoid the selection of
parasite drug resistance [18]. Since large parts of Africa are co-
endemic for malaria and schistosomiasis [22] and both Plasmodium
and Schistosoma parasites degrade hemoglobin, a putative target for
several antimalarial drugs, we were motivated to test other
antimalarials that are commonly employed in combination with
an artemisinin derivative for their potential antischistosomal
activities. We then followed up on the promising in vivo activity
of mefloquine, first to elucidate the dose-response relationships of
single-dose mefloquine against juvenile and adult S. mansoni and S.
japonicum and, second, to assess the stage-specific susceptibility of
both parasites to mefloquine. Finally, we evaluated the activity of
mefloquine (+) and (2) erythro enantiomers against different
developmental stages of S. mansoni.
Materials and Methods
Drugs
Halofantrine, mefloquine HCl, and mefloquine enantiomers
were obtained from Hoffmann La Roche (Basel, Switzerland);
pyronaridine was provided by the National Institute of Parasitic
Diseases, Chinese Center for Disease Control and Prevention
(Shanghai, China); and pyrimethamine, sulfadoxine, and sulfa-
methoxypyrazine were obtained from Dafra Pharma (Turnhout,
Belgium). For the in vivo studies with S. mansoni, lumefantrine was
provided by the Novartis Institute for Biomedical Research (Basel,
Switzerland); amodiaquine, chloroquine, and quinine were
purchased from Sigma (Buchs, Switzerland); and atovaquone
was purchased in a local Swiss pharmacy (WellvoneH). For the in
vivo studies with S. japonicum, lumefantrine was obtained from
Kunming Pharmaceutical Corporation (Kunming, China); and
amodiaquine, atovaquone, chloroquine, and halofantrine were
provided by the National Institute of Parasitic Diseases, Chinese
Center for Disease Control and Prevention (Shanghai, China).
All drugs were prepared as suspensions in7% (v/v) Tween 80 and
3% (v/v) ethanol before oral administration to mice (10 ml/kg).
Animals and parasites
Experiments with S. mansoni (Liberian strain) were carried out at
the Swiss Tropical Institute (Basel, Switzerland), in accordance
with Swiss national and cantonal regulations on animal welfare
(permission no. 1731). Female mice (NMRI strain, n=290, weight
,20–22 g) were purchased from RCC (Itingen, Switzerland).
Mice were kept under environmentally-controlled conditions
(temperature ,25uC; humidity ,70%; 12-hour light and 12-hour
dark cycle) and acclimatized for one week before infection. The
animals had free access to water and rodent diet.
The experiments with S. japonicum (Anhui strain) were
undertaken at the National Institute of Parasitic Diseases, Chinese
Center for Disease Control and Prevention. Male mice (Kunming
strain, n=125, weight ,20–22 g) were purchased from Shanghai
Experimental Animal Center of the Chinese Academy of Sciences
(Shanghai, China).
Cercariae of S. mansoni and S. japonicum were obtained from
infected intermediate host snails in our laboratories as described
previously [13].
In vivo studies with S. mansoni
Each mouse was infected subcutaneously with ,80 S. mansoni
cercariae. Twenty-one days (pre-patent infection) and 49 days
(patent infection) after the experimental infection, groups of 3–5
mice were treated orally with the drugs to be tested at single oral
doses (25–400 mg/kg). To study the stage-specific susceptibility of S.
mansoni, mice were treated with a single 400 mg/kg oral dose of
mefloquine either 2 days or 1 day before infection, 3 hours after
infection or at days 7, 14, 21, 28, 35, 42, and 49 post-infection. For
the hepatic shift experiments groups of mice were treated with
400 mg/kg mefloquine 49 days post-infection, and the worm
distribution was analyzed on days 1, 3, 7 and 14 post-treatment.
Results of the hepatic shift experiments are used as an additional
criterion for evaluating antischistosomal drugs since this test shows
how quickly the forced dislodgement of worms occurs [23]. For each
experiment, groups of 5–10 untreated mice served as controls.
At 21 days post-treatment, animals were killed by the CO2
method and dissected, and worms were sexed and counted as
described elsewhere [13]. In vivo experiments with S. mansoni were
carried out in duplicates. The results from the second set of
experiment are summarized in Supporting Tables S1, S2, and S3.
In vivo studies with S. japonicum
Mice were infected percutaneously with ,40 S. japonicum
cercariae each. To investigate the dose-response relationship of
mefloquine against juvenile and adult S. japonicum, single 25–
400 mg/kg oral doses were given to mice 14 days (pre-patent
infection) and 35 days (patent infection) post-infection. To assess
the efficacy of mefloquine against different stages of S. japonicum,
mice were treated with a single oral dose of 400 mg/kg mefloquine
2 days or 1 day before infection, 3 hours after infection, and at
days 3, 7, 14, 21, 28 and 35 post-infection. In each experiment,
infected but untreated mice served as controls.
Twenty-one days post-treatment, mice were killed and the
worms recovered from the hepatic and portomesenteric veins by
the perfusion technique [24]. To study the hepatic shift in adult S.
Author Summary
Schistosomiasis is a chronic and debilitating disease that
occurs in tropical and subtropical areas. The disease is
caused by an infection with a parasitic worm and affects
over 200 million people. The treatment and control of
schistosomiasis relies on a single drug, praziquantel. This
drug is increasingly used, and hence there is mounting
concern about the development of resistance to prazi-
quantel. Here we report that mefloquine, a marketed drug
for prophylaxis and treatment of malaria, shows promising
antischistosomal properties in laboratory studies with
mice. When mefloquine was orally administered at a
single dose of 200 or 400 mg/kg to mice infected with
young or adult stages of the parasitic worm Schistosoma
mansoni or S. japonicum, we found very high worm burden
reductions. We also found high worm burden reductions
when mefloquine enantiomers were given to mice
infected with adult S. mansoni. Further studies are needed
because our results might be of public health relevance.
Indeed, mefloquine is widely used for prophylaxis and
treatment of malaria, often in areas where both malaria
and schistosomiasis co-exist. In such areas, it might be
possible that the use of mefloquine against malaria
reduces the burden of schistosomiasis.
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35 days post-infection, and the worm distribution was analyzed on
days 1, 3, 7, and 14 post-treatment.
Statistical analysis
For statistical analysis we used version 2.4.5 of the Statsdirect
statistical software package (Cheshire, United Kingdom). The
Kruskal-Wallis (KW) test, which compares the medians of the
responses between the treatment and control groups, was used. A
difference in median was considered to be significant at a
significance level of 5%.
Results
Effect of selected antimalarials on S. mansoni harbored in
mice
The in vivo antischistosomal efficacy of 11 antimalarial drugs is
summarized in Tables 1 and 2. Drugs were administered orally at
a single dose of 400 mg/kg to mice harboring adult S. mansoni, and
worm burden reductions, including changes in worm distributions,
were assessed. Amodiaquine, atovaquone, lumefantrine, pyrimeth-
amine, pyronaridine, sulfadoxine, and sulfamethoxypyrazine
showed no antischistosomal activity. Quinine and halofantrine
resulted in total and female worm burden reductions ranging
between 51.7% and 74.9% and changes in the worm distribution.
The highest activity (total and female worm burden reduction of
77.3% and 100%, respectively) was observed with a single dose of
mefloquine (400 mg/kg), which was statistically significant
(p,0.05). The chemical structures of the four aminoalcohols
quinine, halofantrine, lumefantrine, and mefloquine are shown in
Figure 1.
Dose-response relationships of mefloquine against
juvenile and adult S. mansoni
In view of the promising antischistosomal activity of mefloquine,
its properties were further characterized, with an emphasis on
dose-response relationships in juvenile (21-day-old) and adult (49-
day-old) S. mansoni harbored in mice (Table 3, Table S1). In the
juvenile infection model, total and female worm burden reductions
of 94.2–100% were achieved with a single-dose oral regimen
(100 mg/kg and above). At a dose of 50 mg/kg, the total and
female worm burden reductions were 30.8% and 38.3%,
respectively. At the lowest dose investigated (25 mg/kg) meflo-
quine showed no effect on juvenile S. mansoni in the mouse. The
difference in total and female worm burdens between mice
infected with 21-day-old juvenile S. mansoni that were treated (25–
400 mg/kg) and those mice left untreated was highly significant
(KW=9.51, p=0.002 and KW=8.16, p=0.004, respectively).
Oral administration of mefloquine at a single dose (200 mg/kg
and 400 mg/kg) to mice infected with adult S. mansoni resulted in
total and female worm burden reductions of 72.3–100%. No or
only moderate total and female worm burden reductions (4.9–
56.3%) were achieved with a single dose of 25, 50 or 100 mg/kg
mefloquine. There was a highly significant difference between the
total and female worm burden of mefloquine-treated mice (25–
400 mg/kg) and control mice in the adult infection model
(KW=12.49, p,0.001 and KW=9.46, p=0.002, respectively).
Stage-specific susceptibility S. mansoni
Tables 4 and Table S2 summarizes the activity of mefloquine
when given 2 days or 1 day before infection, shortly after infection
(3 hours post-infection) and until 49 days post-infection. These
experiments were carried out with a single oral dose of 400 mg/kg
mefloquine as this dose achieved the highest reductions in worm
burden against juvenile and adult S. mansoni. A single oral dose of
mefloquine was highly active against mice harboring either a 7-,
14-, 21-, 28-, 35-, 42-, or 49-day-old S. mansoni infection (total and
female worm burden reductions ranged between 83.9% and
100%). Mefloquine administration to mice 2 days or 1 day before
infection or 3 hours after infection showed moderate total and
female worm burden reductions (35.9–46.5%). Regardless of the
timing of mefloquine administration, i.e., shortly before infection
or administration when mice were infected with juvenile or adult
S. mansoni, total and female worm burden reductions were highly
significant (p,0.001).
Table 1. Effect on worm burden of a single oral dose of seven selected antimalarials administered to mice harboring a 49-day-old
adult S. mansoni infection, stratified by sex and worm distribution.
Group
Dose
(mg/kg)
No. of mice
investigated
No. of mice
cured Mean number of worms (SD)
Worm burden
reduction (%)
Liver
Mesenteric
veins Total Males Females Total Female
Control – 5 – 1.4 (0.9) 24.6 (8.4) 26.0 (7.8) 14.0 (3.8) 12.0 (4.0) – –
Amodiaquine 400 3
a 0 1.5 (0.7) 41.5 (6.4) 43.0 (5.7) 22.5 (2.1) 20.5 (3.5) 0 0
Atovaquone 400 3 0 0.3 (0.6) .30 .30 n.d n.d 0 0
Pyrimethamine 100 3
b 0 0 39.0 40.0 21.0 19.0 0 0
Pyronaridine 400 3 0 2.7 (2.1) 24.0 (11.3) 26.7 (9.3) 15.3 (2.9) 11.3 (6.4) 0 5.8
Sulfadoxine 400 3
a 0 0.7 (0.6) 10. 7 (10.5) 28.5 (21.9) 14.5 (10.6) 14.5 (10.6) 0 0
Sulfamethoxypyrazine 400 3
c 0 8.0 (0) 34.5 (7.8) 42.5 (7.8) 27.5 (3.5) 15.0 (4.2) 0 0
Control – 10 – 4.3 (3.3) 30.2 (8.2) 34.3 (8.4) 20.1 (5.3) 14.2 (4.5) – –
Chloroquine 400 5
d 0 2.7 (1.5) 27.3 (4.7) 30.0 (4.4) 17.3 (3.5) 12.7 (2.1) 11.7 0
SD, standard deviation.
aOne mouse died on day 27 post-treatment.
bTwo mice died on days 1 and 2 post-treatment.
cOne mouse died on day 22 post-treatment.
dTwo mice died on days 27 and 30 post-treatment.
doi:10.1371/journal.pntd.0000350.t001
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juvenile and adult S. mansoni
Both (2)(11S,2 9R) and (+)(11R,29S) erythro-enantiomers of
mefloquine resulted in high and comparable total and female
worm burden reductions (p,0.001) when given to mice infected
with either juvenile or adult stages of S. mansoni. At a single dose of
100 mg/kg and above, mefloquine (2)(11S,2 9R) achieved worm
burden reductions of 57.1% to 100% in mice harboring 21-day-
old juvenile and 49-day-old adult S. mansoni. At a single dose of
50 mg/kg, total worm burden reductions of 8.7% to 19.9% were
observed in the juvenile and adult infection model, respectively
(Table 5).
Mefloquine (+)(11R,29S) yielded total and female worm burden
reductions of 64.0% to 100% in mice harboring 21-day-old
juvenile and 49-day-old adult S. mansoni at a single dose of
100 mg/kg and above. At the lowest dose investigated, 50 mg/kg
of mefloquine (+)(11R,29S), we still observed moderate total and
female worm burden reductions (36.0–49.1%).
Dose-response relationships of mefloquine against
juvenile and adult S. japonicum
Table 6 summarizes the dose-response relationship of meflo-
quine against 14-day-old juvenile and 35-day-old adult S. japonicum
in the mouse model. At the lowest dose investigated (25 mg/kg),
total and female worm burden reductions of 16.9% and 10.9%,
respectively, were observed against juvenile S. japonicum. Slightly
higher total and female worm burden reductions (48.9% and
43.6%, respectively) were found when the dose of mefloquine was
doubled (50 mg/kg). Administration of single doses of 100 mg/kg
to 400 mg/kg achieved high total and female worm burden
reductions of 86.7% and 95.1%. There was a highly significant
difference (p,0.001) in the medians of the total and female worm
burden between treated (50–400 mg/kg) and untreated control
mice that were infected with S. japonicum 14 days previously.
Administration of mefloquine at a single-dose of either 25 mg/
kg or 50 mg/kg to mice infected with adult S. japonicum resulted in
total and female worm burden reductions ranging between 16.7%
and 39.7%. A higher dose of mefloquine (100 mg/kg) given to
mice harboring adult S. japonicum resulted in total and female
worm burden reductions of 70.9% and 73.7%, respectively. Total
and female worm burden reductions of 87.5% to 100% were
obtained with mefloquine at 200 mg/kg and 400 mg/kg in the
adult infection model. Total worm counts recovered from treated
(25–400 mg/kg) mice were significantly different from non-treated
control mice infected with adult S. japonicum (KW=10.86,
p=0.001 and KW=9.40, p=0.002, respectively).
Stage-specific susceptibility of S. japonicum
A single oral dose of 400 mg/kg mefloquine was used to
investigate the stage-specific susceptibility of S. japonicum because
this dose showed the highest activities against juvenile and adult
stages of S. japonicum in our previous experiments. Mefloquine
achieved high total and female worm burden reductions ranging
between 77.3% and 100% when administered to mice infected
Table 2. Effect on worm burden of a single 400 mg/kg oral dose of four selected aminomethanol antimalarials administered to
mice harboring a 49-day-old adult S. mansoni infection, stratified by sex and worm distribution.
Group
No. of mice
investigated
No. of
mice
cured Mean number of worms (SD)
Total worm
burden
reduction
(%) KW p-value
Female worm
burden
reduction (%) KW p-value
Liver
Mesenteric
veins Total Males Females
Control 10 – 4.3 (3.3) 30.2 (8.2) 34.3 (8.4) 20.1 (5.3) 14.2 (4.5) – – – – – –
Lumefantrine 5
a 0 2.3 (1.5) 28.7 (4.7) 35.3 (4.0) 18.0 (1.0) 14.0 (3.5) 10.5 0.18 0.671 1.4 0.02 0.864
Mefloquine 4 0 7.0 (3.6) 0.8 (1.5) 7.8 (5.0) 7.8 (5.0) 0 77.3 8.02 0.005 100 9.77 0.002
Quinine 5 0 2.6 (0.9) 13.0 (8.2) 15.6 (7.4) 10.2 (2.9) 5.4 (4.6) 54.7 7.97 0.005 62.0 5.75 0.016
Control 10 – 5.5 (3.1) 38.9 (15.3) 46.6 (14.5) 27.3 (9.3) 18.3 (7.5) – – – – – –
Halofantrine 4 0 16.5 (11.3) 0.5 (1.0) 22.5 (14.2) 16.8 (11.3) 7.8 (3.4) 51.7 4.22 0.039 57.4 6.88 0.009
KW, Kruskal-Wallis; SD, standard deviation.
aTwo mice died on days 17 and 34 post-treatment.
doi:10.1371/journal.pntd.0000350.t002
Figure 1. Chemical structures of mefloquine, quinine, halofan-
trine, and lumefantrine.
doi:10.1371/journal.pntd.0000350.g001
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www.plosntds.org 5 January 2009 | Volume 3 | Issue 1 | e350with S. japonicum for 3 to 35 days (Table 7). Lower total and female
worm burden reductions (26.3–49.2%) were observed when
mefloquine was administered 1 or 3 days before infection (days
1 and 3 prior to infection) or shortly after infection (3 hours post-
infection). The difference in total and female worm burden
reductions between treated and untreated control mice was highly
significant regardless of the point in time mefloquine was
administered (both p,0.001).
Hepatic shift
In Table 8 and Table S3 we summarize the distribution of adult
schistosomes in the liver and mesenteric veins on days 1, 3, 7, and
14 following mefloquine administration in S. mansoni- and S.
japonicum-infected mice. The hepatic shift commenced one day
post-treatment, and nearly all worms had shifted to the liver on
day 3 post-treatment in both infection models. The worm size was
smaller, and the majority of worm pairs were separated. On day
14, the majority of the worms had been eliminated.
Discussion
We report promising antischistosomal properties of mefloquine,
a marketed drug for prophylaxis and treatment of malaria. Oral
administration of a single dose of mefloquine (400 mg/kg) to mice
infected with either juvenile or adult stages of S. mansoni and S.
japonicum, two of the three most important schistosome species [5],
resulted in very high or complete total and female worm burden
reductions. Interestingly, a recent study, which used a lower dose
of mefloquine (150 mg/kg), reported no effect on the worm
burden, but a reduction in egg fecundity in the first three
developmental stages of S. mansoni in the murine model [25]. The
discrepancy of the activity of mefloquine, when administered at
doses of 100 mg/kg or 200 mg/kg to mice infected with adult S.
mansoni observed in our study (worm burden reduction of 45% and
72%, respectively) and the previous investigation (no worm burden
reduction) [25] remains to be elucidated. Previous research has
shown that mefloquine also exhibits a broad spectrum of
antimicrobial activity [26], as well as activity against larval and
adult stages of Brugia patei and B. malayi in vitro [27].
If our results can be confirmed in proof-of-concept studies in
humans, initially with current antimalarial dosages, it is conceiv-
able that mefloquine can play a role in public health because the
drug is widely and effectively used in malaria-endemic settings
[28,29], and because of the fact that malaria and schistosomiasis
co-exist over large parts of sub-Saharan Africa and elsewhere [22].
The highest activities in S. mansoni- and S. japonicum-infected mice
were observed when mefloquine was given at a single oral dose of
200–400 mg/kg, which correspond to 16–31 mg/kg in humans
(dose calculator: http://www.fda.gov/cder/cancer/animalframe.
htm). At present, the recommended dosage of mefloquine is
25 mg/kg when used in human treatment of malaria.
In contrast to other recently portrayed schistosomicides such as
the oxadiazoles [10] or the cysteine protease inhibitor K11777
[14], which thus far have only been tested intraperitoneally and in
multiple doses, mefloquine at a single oral dose resulted in high
worm burden reductions. Moreover, the consistently high worm
burden reductions observed against all development stages of the
schistosome worms in the rodent model seems to be an advantage
of mefloquine over praziquantel; the latter only displaying high
activity against very young stages (skin penetration) and adult
schistosomes [30,31]. Actually, the minor activity of praziquantel
against juvenile (2- to 3-week-old) schistosomes is believed to be a
key factor explaining observed treatment ‘failures’ in areas highly
endemic for schistosomiasis and that require frequent retreatments
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www.plosntds.org 7 January 2009 | Volume 3 | Issue 1 | e350[11,32,33]. For comparison, the stage-specific susceptibility of
praziquantel and mefloquine are juxtaposed in Figure 2. It is
evident that mefloquine exceeds benchmark criteria set forth by
the World Health Organization (WHO) for highly active lead
compounds (defined as worm burden reduction of .80% in the
adult S. mansoni-mouse model following five consecutive doses
given intraperitoneally or subcutaneously) [34]. We approached or
exceeded this benchmark level with a single dose of 400 mg/kg
given orally to mice infected with either adult or juvenile stages of
S. mansoni and S. japonicum.
Single oral doses of the antimalarials amodiaquine, atovaquone,
sulfadoxine, sulfamethoxypyrazine, pyronaridine and pyrimeth-
amine showed no activity in the S. mansoni-mouse model. A single
oral dose of chloroquine also had no activity in the S. mansoni-
mouse model, while previous work documented antischistosomal
properties when the drug was given as multiple intraperitoneal
doses [35]. On the other hand, quinine and halofantrine, which
are structurally related to mefloquine, exhibited promising
antischistosomal properties in the mouse (total worm burden
reductions .50% following a single-dose oral regimen). The lack
of antischistosomal activity of oral lumefantrine, which also
belongs to the class of aminoalcohols, might be explained by the
low oral bioavailability of this drug [36]. Further studies with
intraperitoneal lumefantrine in S. mansoni-infected mice are
ongoing in our laboratories. Interestingly, oxamniquine, a drug
that has been widely and effectively used for the treatment and
Table 6. Dose response relationship of mefloquine administered to mice harboring either a 14-day-old juvenile or a 35 day-old
adult S. japonicum infection.
Stage of
infection
Dosage
(mg/kg)
No. of mice
investigated
No. of
mice
cured Mean number of worms (SD)
Total worm
burden
reduction (%) KW p-value
Female worm
burden
reduction (%) KW p-value
Total Males Females
Juvenile – 8 – 22.5 (8.3) 12.4 (3.4) 10.1 (2.9) – 12.19 ,0.001 – 11.60 ,0.001
25 6 0 18.7 (6.0) 9.7 (3.5) 9.0 (2.5) 16.9 10.9
50 6 0 11.5 (6.4) 5.8 (3.2) 5.7 (3.3) 48.9 43.6
100 6 1 3.0 (2.8) 1.8 (1.7) 1.2 (1.2) 86.7 88.1
200 5 3 1.4 (2.2) 0.6 (0.9) 0.8 (1.3) 93.8 92.1
400 6 4 1.2 (2.0) 0.7 (1.2) 0.5 (0.8) 94.7 95.1
Adult – 5 – 27.2 (4.4) 16.2 (4.4) 11.4 (1.3) – 10.86 0.001 – 9.40 0.002
25 4 0 20.0 (5.4) 10.5 (3.1) 9.5 (2.4) 26.4 16.7
50 8 0 16.4 (8.6) 8.5 (4.5) 7.9 (4.1) 39.7 30.7
100 8 0 7.9 (5.4) 4.9 (2.7) 3.0 (3.1) 70.9 73.7
200 8 0 3.4 (2.7) 3.3 (2.5) 0.1 (0.4) 87.5 99.1
400 8 4 1.3 (1.4) 1.3 (1.4) 0 95.2 100.0
Worm burden is stratified by sex and worm distribution.
KW, Kruskal Wallis test; SD, standard deviation.
doi:10.1371/journal.pntd.0000350.t006
Table 7. Stage specificity of a single 400 mg/kg oral dose of mefloquine administered to mice infected with S. japonicum,
stratified by sex.
Drug
administration
No. of mice
investigated
No. of
mice
cured Mean number of worms (SD)
Total worm
burden
reduction (%) KW p-value
Female worm
burden
reduction (%) KW p-value
Total Males Females
Control 5 – 27.2 (4.4) 16.2 (4.4) 11.4 (1.3) - 12.51 ,0.001 – 12.59 ,0.001
Pre-infection Day -2 5 0 16.8 (5.3) 9.8 (3.3) 7.0 (2.7) 38.3 38.6
Day -1 5 0 18.0 (3.4) 10.4 (3.1) 8.4 (1.5) 33.4 26.3
Day 0 4 0 15.5 (5.4) 9.8 (3.5) 5.8 (2.2) 43.0 49.2
Post-infection Day 3 4 0 4.8 (1.9) 2.5 (1.0) 2.3 (1.0) 82.4 79.8
Day 7 5 0 3.4 (1.3) 2.0 (0.7) 1.4 (0.9) 87.5 87.7
Day 14 4 3 0.5 (1.0) 0.3 (0.5) 0.3 (0.5) 98.2 97.4
Day 21 5 0 6.2 (5.0) 3.4 (2.6) 2.8 (3.1) 77.3 75.4
Day 28 5 0 5.8 (2.6) 4.6 (2.6) 1.2 (1.3) 78.8 89.5
Day 35 5 1 2.0 (1.2) 2.0 (1.2) 0 92.6 100.0
KW, Kruskal-Wallis test; SD, standard deviation.
doi:10.1371/journal.pntd.0000350.t007
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more than 12 million people have been administered this drug
[37], also contains an aminoalcohol functionality [38].
Importantly, previous investigations on the morphology of
schistosomes recovered from host animals after administration of
praziquantel [39] and observations made with schistosomes
collected from mefloquine-treated mice point to different mech-
anisms of actions. Results obtained from preliminary morpholog-
ical investigations (no data shown) indicate that mefloquine exerts
a rapid action on schistosomes, resulting in marked alterations of
the digestive tract and the reproductive system of the worms. The
detailed mechanism of action of mefloquine and related
aminoalcohols on schistosomes remains to be investigated. Still
today, the exact mechanism of action of mefloquine on Plasmodium
is not known, though interference with hemoglobin digestion
seems to play a role [40]. It was demonstrated that the antimalarial
chloroquine inhibits the formation of hemozoin, a heme
detoxification aggregate in S. mansoni female homogenates [35],
hence future studies should elucidate whether mefloquine also
targets hemozoin formation. It is interesting to note that adult
female S. mansoni were more affected by mefloquine at doses of
100–400 mg/kg than male adult S. mansoni. This phenomenon was
not observed when treating juvenile stages of either S. mansoni or S.
japonicum. Differences in drug susceptibility between male and
female S. mansoni have been reported previously, e.g., following
hycanthone treatment [41] and point to a sex-specific interference
of the drug with the target, or different drug targets.
Interestingly, moderate worm burden reductions were found
whenasingledoseofmefloquinewasgivenoneortwodaysbeforeor
three hours after infection of mice with either S. mansoni or S.
japonicum. Although mefloquine hasa longhalf-life of6.5to22.7days
in healthy volunteers [42], the half-life of this drug in mice is much
shorter,namely17 hours[43].Furtherstudies shouldbe launched to
clarify whether active metabolites, the significant enterohepatic
recirculation of mefloquine found in rodents [44] or a treatment
induced alteration of the immune response, which has, for example,
been described for praziquantel, [45] may be a contributing factorto
the efficacy and be partly responsible for the moderate worm burden
reductions recorded when mefloquine is given pre-infection. Pro-
inflammatory effects of mefloquine have been described in both S.
mansoni-infected and non-infected mice [25].
Table 8. Hepatic shift test following a single 400-mg/kg oral dose of mefloquine administered to mice infected with S. mansoni
and S. japonicum.
Schistosome
species
Day of analysis
post-treatment
No. of mice
investigated Number of worms liver
Number of worms mesenteric
veins
Total worm
burden
Mean (SD) % Mean (SD) % Mean (SD)
S. mansoni Control 10 4.3 (1.9) 12.0 31.6 (6.4) 88.0 35.9 (6.3)
Day 1 5 16.2 (1.6) 37.9 26.6 (6.8) 62.1 42.8 (6.5)
Day 3 5 37.0 (4.1) 96.4 1.4 (2.2) 3.6 38.4 (4.2)
Day 7 4 9.3 (4.1) 100 0 0 9.3 (4.1)
Day 14 5 5.8 (2.8) 100 0 0 5.8 (2.8)
S. japonicum Control 5 0.2 (0.4) 1.2 16.2 (2.5) 98.8 16.4 (2.3)
Day 1 5 11.5 (7.9) 47.3 12.8 (11.1) 52.7 24.3 (6.2)
Day 3 4 18.6 (4.0) 100 0 0 18.6 (4.0)
Day 7 5 12.2 (1.9) 95.3 0.6 (0.9) 4.7 12.8 (2.4)
Day 14 5 5.6 (2.2) 87.5 0.8 (1.8) 12.5 6.4 (2.6)
SD, standard deviation.
doi:10.1371/journal.pntd.0000350.t008
Figure 2. Stage-specific susceptibility of mefloquine compared
to praziquantel in the S. mansoni- and S. japonicum-mouse
models. Red squares: mefloquine 400 mg/kg, blue circles: praziquantel
400 mg/kg. The stage-specific susceptibilities of praziquantel and
mefloquine on S. mansoni have been established in the laboratories
of the Swiss Tropical Institute (Basel, Switzerland). The efficacy of
praziquantel against S. japonicum has been reported by Yue et al. [51]
and that of mefloquine has been established at the laboratories of the
National Institute of Parasitic Diseases (Shanghai, China).
doi:10.1371/journal.pntd.0000350.g002
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However, there is evidence that mefloquine may result in harmful
events in the gastrointestinal and central nervous systems.
Observed adverse events include insomnia, nausea, vomiting,
diarrhea, headache, dizziness, rash, pruritus, and abdominal pain.
Severe neuropsychiatric symptoms as seizures and hallucinations
are rare (occurring in 1 per 10,000 patients) [46]. Adverse events
seem to be dose-dependent, and it was suggested that doses greater
than 15 mg/kg should be divided [42]. To date, the neurotoxicity
of mefloquine cannot be explained, and it remains to be elucidated
whether there is steroselectivity in the neurotoxic potencies of the
enantiomers. However, the brain penetration of the (+) enantio-
mer was found to be much higher than that of the (2) enantiomer
in two post-mortem human cerebral biopsies [47]. We have
demonstrated that both enantiomers and the racemic hydrochlo-
ride possess a similar activity against juvenile and adult S. mansoni.
Interestingly, this finding contrasts with the activity of mefloquine
in Plasmodium yoelii-infected mice, where the racemic hydrochloride
of mefloquine showed a two-fold to three-fold higher activity when
compared to the enantiomers, which had similar activity to each
other [48].
In conclusion, we have documented promising in vivo antischis-
tosomal efficacy of the antimalarial drug mefloquine. New studies
have been launched with an aim to elucidate the effect of
mefloquine on the third major schistosome species, i.e., S.
haematobium, and a number of the biologically-related trematodes
such as Clonorchis sinensis and Opisthorchis viverrini. Additionally, in
vitro studies and an evaluation of the potential of praziquantel-
mefloquine combination therapy have been initiated. Finally, a
proof-of-concept study will be launched in an African setting,
where malaria and schistosomiasis co-exist, similar to our
preceding work with the artemisinins [49,50]. A word of caution
should be mentioned here, as the malaria community has argued
that antimalarial drugs should not be used against schistosomiasis
because of concern that this strategy might select for Plasmodium-
resistant parasites. However, millions of people have been, or will
be, treated with mefloquine and mefloquine-artesunate combina-
tions in areas where both malaria and schistosomiasis co-exist [22].
Hence, the potential ancillary benefit of the antimalarial drug
mefloquine should be investigated against schistosomiasis.
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